After decades of research by the global academic community, Quintrigen is on the road to reignite mutant p53 protein, putting it back to work. We are guided by an exceptional team of world-renowned scientists from the Weizmann Institute in Israel, backed by BioLeaders of Korea, and we are taking a new strategy to reignite p53’s activity. By transforming it from mutant to normal again, we expect to impact the lives of millions of cancer patients worldwide.